This report was first published by Endpoints News. To see the original version, click here
Novo Nordisk is looking into acquiring or developing a long-acting GLP-1 drug that could compete with Pfizer’s monthly obesity shot. It has also cut a handful of drugs from its pipeline, so it certainly has room to add more candidates.
Pfizer beat Novo in the ferocious battle to acquire the long-acting GLP-1 developer Metsera in November. The data on Pfizer’s monthly shot, which came out Tuesday, were somewhat limp, and some have questioned whether the company overpaid.
您已阅读12%（563字），剩余88%（4061字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。